Narrow search
Showing 1 - 10 of 3,496
Cover Image
Measuring the acceptability of EQ-5D-3L health states for different ages : a new adaptive survey methodology
Hermann, Zoltán; Péntek, Márta; Gulácsi, László; … - In: The European journal of health economics 23 (2022) 7, pp. 1243-1255
Persistent link: https://www.econbiz.de/10013407247
Cover Image
Strategic corporate social responsibility and orphan drug development : insights from the US and the EU biopharmaceutical industry
Bruyaka, Olga; Zeitzmann, Hanko K.; Chalamon, Isabelle; … - In: Journal of business ethics : JOBE 117 (2013) 1, pp. 45-65
Persistent link: https://www.econbiz.de/10010231737
Cover Image
Improving access to rare disease treatments : subsidy, pricing, and payment schemes
Olsder, Wendy; Martagan, Tugce; Tang, Christopher S. - In: Management science : journal of the Institute for … 69 (2023) 9, pp. 5256-5274
Persistent link: https://www.econbiz.de/10014392908
Cover Image
Opportunities and barriers for innovation and entrepreneurship in orphan drug development
Belousova, Olga A.; Groen, Aard J.; Ouendag, Aniek M. - In: Technological forecasting & social change : an … 161 (2020), pp. 1-11
Persistent link: https://www.econbiz.de/10012533698
Cover Image
Are some QALYs more equal than others?
Wetering, E. J. van de; Exel, N. J. A. van; Rose, John M.; … - In: The European journal of health economics : HEPAC ; … 17 (2016) 2, pp. 117-127
Persistent link: https://www.econbiz.de/10011486401
Cover Image
Q-ing for health : a new approach to eliciting the public's views on health care resource allocation
Baker, Rachel; Wildman, John; Mason, Helen; Donaldson, Cam - In: Health economics 23 (2014) 3, pp. 283-297
Persistent link: https://www.econbiz.de/10010336141
Cover Image
Why do health technology assessment coverage recommendations for the same drugs differ across settings? : applying a mixed methods framework to systematically compare orphan drug d...
Nicod, Elena - In: The European journal of health economics : HEPAC ; … 18 (2017) 6, pp. 715-730
Persistent link: https://www.econbiz.de/10011868947
Cover Image
Corporate Social Responsibility (CSR) of innovative pharmaceutical corporations : the case of BIOGEN
Witkowska, Janina - In: Comparative economic research : Central and Eastern Europe 21 (2018) 3, pp. 45-62
The aim of this paper is to discuss the common features and specificity of Corporate Social Responsibility (CSR) practices of innovative transnational corporations (TNCs) acting in the pharmaceutical industry. The innovativeness of pharmaceutical firms is understood here as their ability to make...
Persistent link: https://www.econbiz.de/10011960021
Cover Image
Rethinking institutional entrepreneurship : the case of the construction of orphan drug field in Europe
Hamadache, Karim; Brabet, Julienne - In: Society and business review 9 (2014) 2, pp. 139-152
Persistent link: https://www.econbiz.de/10010401325
Cover Image
Comparative effectiveness research and the rise of orphan indications
Jeffers, Sarah; Slomiany, Mark; Bitar, Rema; Kruse, Sarah; … - In: International journal of pharmaceutical and healthcare … 8 (2014) 2, pp. 151-163
Persistent link: https://www.econbiz.de/10010388963